DC
Therapeutic Areas
LoQus23 Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Somatic Expansion Inhibitor Program | Huntington's Disease | Preclinical |
| Platform Expansion | Other Triplet Repeat Expansion Disorders | Research |
Leadership Team at LoQus23 Therapeutics
DD
Dr. David Reynolds
Chief Executive Officer & Co-founder
DC
Dr. Caroline Benn
Chief Scientific Officer & Co-founder
DD
Dr. David Hardick
Head of Chemistry
DA
Dr. Amanda Davis
VP of Operations and Development
DT
Deb Tonge
Finance Director